Loading…
Administration of a strain of A. muciniphila improved the anti-tumor activity following treatment with anti-PD1 agents in both germ-free mice transplanted with stool from non-responders and in mice pre-exposed to antibiotics
A. muciniphila is a promising candidate to enhance the clinical response to Immune Checkpoint Inhibitors (ICIs) Therapy
Akkermansia muciniphila has been robustly associated with positive systemic effects on host metabolism, favourable outcomes to checkpoint blockade in cancer immunotherapy and homeostatic immunity
Routy et al. 2018
Depommier et al. 2019 Nat Med. 25(7): 1096-1103
A statistically powered study aimed to specifically evaluate the association between the baseline detection of A. muciniphila and clinical response in 338 patients with non-small-cell lung cancer
It was first reported in a mixed population of patients with advanced renal and lung cancers that A. muciniphila was the main bacterium associated with the best response and progression-free survival at three months during PD-1 blockade. This finding was then prospectively validated in a study of 311 patients with non-small cell lung cancer (NSCLC). Of these, about 50% were A. muciniphila positive. The study showed that objective responders harbored A. muciniphila in about 65% of cases. For those with stable and progressive disease, 48% were A. muciniphila positive. Patients that harbored A. muciniphila had a median overall survival of 19 months, compared with 11.4 months in A. muciniphila-negative patients. Harboring A. muciniphila in the gut was associated with increased richness of the microbiome, as measured by Shannon diversity.
There were two groups with different taxonomic compositions: one was associated with prolonged overall survival, and the other with shorter overall survival. Researchers segregated patients according to the 25th to 75th percentile for the relative abundance of A. muciniphila and found that normal relative abundance of A. muciniphila predicted sensitivity to therapy, while high relative abundance predicted resistance to therapy.
Zitvogel AACR 2021
Clinical responses to immune checkpoint inhibitors are correlated with relative abundance of Akkermansia muciniphila
Routy et al. 2018
see also:
Akkermansia muciniphila & Anti-PD-1 antibodies / PD-1 inhibitors
Anti-PD-1 antibodies / PD-1 inhibitors & Gut microbiota
Fecal Microbiota Transplantation (FMT) (procedure-based) & Preclinical/Clinical data
Gut microbiota & Immune Checkpoint Inhibitors (ICIs)
Immune Checkpoint Inhibitors (ICIs) & Non-small-cell lung carcinoma (NSCLC)